Thirty years of BCL-2: translating cell death discoveries into novel cancer therapies

By A. R. Delbridge, S. Grabow, A. Strasser, David L. Vaux. Nature Reviews. Cancer, 2016

709 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Synthetic Lethality of Combined Bcl-2 Inhibition and p53 Activation in AML: Mechanisms and Superior Antileukemic Efficacy (2017, background): “For most cancer treatments, including chemotherapy, radiotherapy, and targeted therapies, induction of apoptosis represents the principal mechanism by which malignant cells are eliminated (Delbridge et al., 2016; Hata et al., 2015; Letai, 2008).”
BCL-2 family proteins: changing partners in the dance towards death (2017, background): “ABT-199 is approved for use in chronic lymphocytic leukemia and both drugs are being used in dozens of clinical trials as single agents and in combination with other therapies.(109) Some cancers depend primarily on MCL-1 for survival and others acquire resistance to drugs that target BCL-2/BCL-XL/BC”
Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death 2018 (2018, background): “MOMP directly promotes the cytosolic release of apoptogenic factors that normally reside in the mitochondrial intermembrane space [40, 44, 156].”